Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 16/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.49 |
| ▸ | NPC1 | O15118 | 8/20 | 0.49 |
| ▸ | RAB9A | P51151 | 8/20 | 0.49 |
| ▸ | COMT | P21964 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21525701 | 0.83 | CCR1 (0.47) | KDM4EL3MBTL1MMP2TSHRMAPT | |
| SCHEMBL686939 | 0.82 | KDM4E (0.53) | KDM4EL3MBTL1NPC1RAB9ACOMT | |
| SCHEMBL23330367 | 0.81 | LMNA (0.40) | KDM4EMMP2TSHRMAPTNFKB1 | |
| SCHEMBL15217635 | 0.79 | KDM4E (0.53) | KDM4EL3MBTL1NPC1RAB9ACOMT | |
| SCHEMBL27019878 | 0.78 | CCR1 (0.57) | KDM4EL3MBTL1MMP2TSHRMAPT | |
| SCHEMBL15217628 | 0.78 | KDM4E (0.56) | KDM4EL3MBTL1NPC1RAB9ACOMT | |
| SCHEMBL25113961 | 0.76 | KDM4E (0.53) | KDM4EL3MBTL1NPC1RAB9ACOMT | |
| SCHEMBL3432556 | 0.75 | KDM4E (0.52) | KDM4EL3MBTL1NPC1RAB9ACOMT | |
| SCHEMBL6897816 | 0.75 | KDM4E (0.49) | KDM4EL3MBTL1NPC1RAB9ACOMT | |
| SCHEMBL11686678 | 0.75 | TRPV1 (0.59) | KDM4EL3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200030716-A1 | TASK SPECIFIC CHELATING IONIC LIQUIDS FOR REMOVAL OF METAL IONS FROM AQUEOUS SOLUTION VIA LIQUID/LIQUID EXTRACTION AND ELECTROCHEMISTRY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-01-30 | — | — | US | disclosed |
| US-9963433-B2 | Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor | WAYNE STATE UNIVERSITY (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170217903-A1 | ANTICANCER DRUGS INCLUDING THE CHEMICAL STRUCTURES OF AN ANDROGEN RECEPTOR LIGAND AND A HISTONE DEACETYLASE INHIBITOR | WAYNE STATE UNIVERSITY | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217903-A1 | ANTICANCER DRUGS INCLUDING THE CHEMICAL STRUCTURES OF AN ANDROGEN RECEPTOR LIGAND AND A HISTONE DEACETYLASE INHIBITOR | AR, HDAC1, HDAC11 | KDM4E 261/4885L3MBTL1 4263/4885NPC1 2397/4885 |
| US-20200030716-A1 | TASK SPECIFIC CHELATING IONIC LIQUIDS FOR REMOVAL OF METAL IONS FROM AQUEOUS SOLUTION VIA LIQUID/LIQUID EXTRACTION AND ELECTROCHEMISTRY | SOD1, SOD3, SLC39A11 | KDM4E 3493/4885L3MBTL1 712/4885NPC1 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.